Giovanni Bellomo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6568236/publications.pdf

Version: 2024-02-01

22 papers

465 citations

759233 12 h-index 19 g-index

25 all docs 25 docs citations

25 times ranked

795 citing authors

#	Article	IF	CITATIONS
1	Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers. Movement Disorders, 2022, 37, 669-683.	3.9	30
2	Quantification of SPECT Concentric Ring Artifacts by Radiomics and Radial Features. Applied Sciences (Switzerland), 2022, 12, 2726.	2.5	0
3	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.8	26
4	Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 6922.	4.1	2
5	Revisiting paramagnetic relaxation enhancements in slowly rotating systems: how long is the long range?. Magnetic Resonance, 2021, 2, 25-31.	1.9	2
6	Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for \hat{l}_{\pm} -synuclein measurement. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1653-1661.	2.3	2
7	An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?. International Journal of Molecular Sciences, 2021, 22, 5991.	4.1	28
8	Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics. Cells, 2021, 10, 1930.	4.1	34
9	Seed amplification assays for diagnosing synucleinopathies: the issue of influencing factors. Frontiers in Bioscience, 2021, 26, 1075.	2.1	9
10	The Vicious Cycle Between α â€Synuclein Aggregation and Autophagicâ€Lysosomal Dysfunction. Movement Disorders, 2020, 35, 34-44.	3.9	77
11	Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?. Alzheimer's Research and Therapy, 2020, 12, 121.	6.2	6
12	A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies. Diagnostics, 2020, 10, 1015.	2.6	16
13	CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. Trends in Pharmacological Sciences, 2020, 41, 1023-1037.	8.7	48
14	Measurement of CSF core AD biomarkers for routine clinical diagnosis: Do fresh vs frozen samples differ?. Alzheimer's and Dementia, 2020, 16, e043664.	0.8	0
15	CSF ADâ€ike profile in SCD, preâ€MCI and MCI subjects: Application of the A/T/N classification model in a retrospective cohort from a memory clinic. Alzheimer's and Dementia, 2020, 16, e043990.	0.8	O
16	Multivariate Curve Resolution for 2D Solid-State NMR spectra. Analytical Chemistry, 2020, 92, 4451-4458.	6.5	15
17	The issue of waste disposal in Parkinson's disease pathogenesis. Movement Disorders, 2019, 34, 985-985.	3.9	3
18	Parkinson's and Lewy body dementia CSF biomarkers. Clinica Chimica Acta, 2019, 495, 318-325.	1.1	38

#	Article	IF	CITATIONS
19	Dissecting the Interactions between Human Serum Albumin and α-Synuclein: New Insights on the Factors Influencing α-Synuclein Aggregation in Biological Fluids. Journal of Physical Chemistry B, 2019, 123, 4380-4386.	2.6	25
20	Aggregation kinetics of the AÎ21â \in 40 peptide monitored by NMR. Chemical Communications, 2018, 54, 7601-7604.	4.1	29
21	Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of "Protein-Misfolding Cyclic Amplification―and "Real-Time Quaking-Induced Conversion―as Diagnostic Tools. Frontiers in Neurology, 2018, 9, 415.	2.4	66
22	MR Spectroscopy in Prostate Cancer: New Algorithms to Optimize Metabolite Quantification. PLoS ONE, 2016, 11, e0165730.	2.5	7